28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
AADAPt participants had risk factors for developing dementia in future, such as hypertension and hyperlipidemia, but also reported protective factors such as high social engagement. 2 key findings →
Design: longitudinal study Participants: 177 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Despite the growth in Medicare managed care enrollment, only 9 papers report the costs of care for individuals with ADRD within these plans, and only 1 study reports data less than 10 years old. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Our sample included 1001 participating and 3873 matched control SNFs. 5 key findings →
Design: cohort study Participants: 1,001 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Racial/ethnic groups differed in sources of recruitment, reasons for screen failure, and overall probability of eligibility in a preclinical AD trial. 5 key findings →
Design: cross-sectional Participants: 5,945 Evidence: low
Full summary, score breakdown and related studies → Original source
We conclude that dementia and cognitive impairment are common among older adults with hip fractures. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Individuals with AD comprise a substantial number of older adult deaths in the United States, a number expected to rise considerably in coming decades. 1 key finding →
Design: longitudinal study Participants: 10,802 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The findings of this study suggest an increased risk of dementia among individuals with TBI. 3 key findings →
Design: cohort study Participants: 44,925 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dialysis modality is associated with incident dementia in a cohort of older ESRD patients. 4 key findings →
Design: cohort study Participants: 121,623 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dual-eligible older persons are at greater risk for decline in function and cognition after an ICU hospitalization than their more advantaged counterparts. 2 key findings →
Design: cohort study Participants: 641 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dementia is among various diseases affecting the elderly, who is also at a high risk for fractures. 3 key findings →
Design: cohort study Participants: 66,797 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Deintensification of treatment regimens occurred in less than one-half of potentially overtreated Veterans and was more strongly associated with low HbA1c values and use of medications with high risk for hypoglycemia, rather than other resident characteristics. 5 key findings →
Design: cohort study Participants: 3,056 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Median survival was much lower than in screened populations. 3 key findings →
Design: cohort study Participants: 22 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neurodegenerative disease in patients with chronic obstructive pulmonary disease (COPD) was observed. 2 key findings →
Design: cohort study Participants: 8,640 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Preventable hospital readmissions have been recognized as indicators of hospital quality, a source of increased healthcare expenditures, and a burden for patients, families, and caregivers. 2 key findings →
Design: cohort study Participants: 5,133 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Careful consideration of model specification and the profound effects of mortality selection in the older adult population is essential when investigating the relationship between aging-related diseases such as cancer and AD. 4 key findings →
Design: cohort study Participants: 92,425 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Included in the analysis were 48,330 participants across 46 ADRCs (mean [SD] age, 71.3 [10.5] years; 20,767 female [57%]; 4,138 Hispanic [8.6%]; 1,392 non-Hispanic Asian [2.9%]; 6,766 non-Hispanic Black [14%] individuals; and 676 individuals [1.4%] of other races. 4 key findings →
Design: cross-sectional Participants: 48,330 Evidence: low
Full summary, score breakdown and related studies → Original source
Two models comprising behavior change and psychological impact fit well for the total sample and the two racial groups. 5 key findings →
Design: longitudinal study Participants: 334 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The sample included 1 626 127 Medicare beneficiaries (mean [SD] age, 80.1 [8.0] years; 922 194 women [56.7%]) who received diagnoses of the 4 conditions in 2016. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Short-term mortality is increased in patients newly diagnosed with probable AD. 5 key findings →
Design: longitudinal study Participants: 327 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Program participants (n = 382 men, n = 701 women; mean [SD] age, 82.10 [7.90] years; age range 54-101 years) were less likely to be admitted to a long-term care facility (hazard ratio, 0.60; 95% CI, 0.59-0.61) than those not participating in the dementia care program (n = 759 men, n = 1407 women; mean [SD] age, 82.42 [8.50] years; age range, 34-103 years). 1 key finding →
Design: case-control study Participants: 382 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The eRADAR tool uses existing EHR data to detect patients with good accuracy who may have unrecognized dementia. 1 key finding →
Design: cohort study Participants: 4,330 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Individuals aged 68+ years diagnosed with OAG have a decreased rate of AD or other dementia diagnosis compared to control patients without an OAG diagnosis. 3 key findings →
Design: cohort study Participants: 63,235 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In total, 6,683 participants were included. 5 key findings →
Design: cross-sectional Participants: 6,683 Evidence: low
Full summary, score breakdown and related studies → Original source
This study examined the impact of advance care planning (ACP) on healthcare utilization among older adults with normal cognition and impaired cognition/dementia. 1 key finding →
Design: cross-sectional Participants: 17,698 Evidence: low
Full summary, score breakdown and related studies → Original source
Successful discharge of beneficiaries with ADRD increased from 43.4% in 2007 to 53.9% in 2015 (average annual percent change (AAPC) = 2.1 (95% CI = 2.0-2.2)); those without ADRD also increased (from 59.1% to 63.6%, AAPC = 0.9 (95% CI = 0.7-1.1)) but not as fast as those with ADRD (P < .01). 4 key findings →
Design: cross-sectional Participants: 17,043 Evidence: low
Full summary, score breakdown and related studies → Original source
9 of the 267 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →